ASH 2020 | Acalabrutinib monotherapy in R/R MCL: extended follow-up results
Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the follow-up results of a Phase II study (NCT02213926) aiming to assess the efficacy and safety of acalabrutinib monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients. After a median follow-up of 38 months, the overall response rate was 81%, with 48% of the participants achieving a complete response. This long-term follow up has shown us an improved safety profile of acalabrutinib monotherapy. With an impressive median duration of response (DOR) of 28.6 months, a median progression-free survival (PFS) of 22 months and an estimated 36-month overall survival rate of 61%, acalabrutinib certainly has potential as a novel treatment in R/R MCL patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Michael Wang has received grants from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, Juno, Loxo Oncology, VelosBio, BioInvent, Kite Pharma, Verastem, BeiGene, Eli Lilly, InnoCare and Molecular Templates; has received personal fees from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, OMI, Pulse Biosciences, Juno, Loxo Oncology, VelosBio, Targeted Oncology, Kite Pharma, Guidepoint Global, BeiGene, InnoCare and Oncternal; has received non-financial support from Pharmacyclics, Celgene, Janssen and OMI.
